- 46.7k views
Use of Oral Glycemic Drugs in CKD
The use of oral glycemic drugs in patients with Chronic Kidney Disease (CKD) requires careful consideration due to altered drug metabolism and excretion associated with kidney dysfunction. Metformin, often the first-line treatment for type 2 diabetes, may be used with caution in mild to moderate CKD but is contraindicated in advanced stages due to the risk of lactic acidosis. Sulfonylureas, except for gliclazide and glimepiride, are generally avoided in CKD because of the prolonged hypoglycemia risk. DPP-4 inhibitors are safer options but may require dose adjustments based on renal function. SGLT2 inhibitors, beneficial for their cardiovascular and renal protective effects, are increasingly recommended, though some are contraindicated in severe CKD. GLP-1 receptor agonists offer a safer profile for CKD patients, with liraglutide and semaglutide being viable options. Ultimately, individualized treatment, frequent monitoring, and adjustments of oral hypoglycemic agents are crucial in managing diabetes in CKD patients.
About the Speaker
Dr. Adarsh K.S.
Consultant in Dept of Endocrinology, Manipal Hospitals,Bangalore
Adarsh K S is a distinguished Consultant in the Department of Endocrinology at Manipal Hospitals in Bangalore, with an extensive educational background comprising an MBBS, MD in Medicine, and a DM in Endocrinology from some of India's prestigious institutes.
Upcoming Case Discussions
Scale Healthcare Brands with AI-Powered Marketing
The AI revolution in medicine is transforming healthcare, making it smarter and more efficient than ever before. From early disease detection to personalized treatment plans, AI empowers doctors with data-driven insights for better decision-making. Robotic surgeries and AI-assisted diagnostics are enhancing precision and reducing human error. AI also improves patient care through virtual assistants and remote monitoring tools. This technological leap is paving the way for a future where healthcare is more accessible, accurate, and innovative.
Comprehensive Approaches to Pediatric Practice
Comprehensive approaches to pediatric practice emphasize holistic care that integrates early screening, preventive measures, and tailored treatments. These strategies involve using tools like the NISA card for early detection of conditions such as iron deficiency anemia. Regular anthropometric assessments provide insight into growth and development, allowing for early intervention. Incorporating neurodevelopmental screening tools ensures that cognitive, emotional, and physical milestones are monitored effectively. Collaborative care models, including parental involvement and education, support continuous patient engagement. Digital health tools can enhance monitoring and streamline consultations. Multidisciplinary teams can address complex cases more efficiently. Preventive care and health education are prioritized to reduce long-term risks. Comprehensive approaches foster a proactive environment that adapts to each child's needs. The result is improved health outcomes and overall child well-being.
Case Based Discussion on Bronchiolitis
Bronchiolitis is a common respiratory infection in infants and young children, primarily caused by the respiratory syncytial virus (RSV). It presents with nasal congestion, cough, wheezing, and difficulty breathing, often following an upper respiratory infection. Management is largely supportive, focusing on hydration, oxygen therapy, and suctioning nasal secretions. Routine use of bronchodilators, steroids, or antibiotics is not recommended. Severe cases may require hospitalization for respiratory support, such as high-flow nasal cannula or mechanical ventilation. Preventive measures include proper hand hygiene and, in high-risk infants, palivizumab prophylaxis. Prompt recognition and appropriate care are key to reducing complications and improving outcomes.
Diabetic Complications in 12 Questions
Diabetic complications in 12 Questions" is designed to address common concerns related to the long-term effects of diabetes, such as neuropathy, retinopathy, and cardiovascular issues. Through a Q&A format, the session aims to educate participants on prevention, early detection, and management strategies for these complications to improve overall diabetic care.
Management of ICU Delirium
The management of ICU delirium involves a combination of preventive strategies, such as early mobilization, minimizing sedation, and addressing underlying medical causes, to reduce the risk and severity of delirium in critically ill patients. Treatment includes optimizing the patient's environment, using non-pharmacological interventions, and, if necessary, medications to manage symptoms while focusing on long-term cognitive recovery.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Adarsh K.S. 's Talks on Assimilate
- 30th-January-2024, TIME : 5:00PM - 6:00PM
- 0
The use of oral glycemic drugs in patients with Chronic Kidney Disease (CKD) requires careful consideration due to altered drug metabolism and excretion associated with kidney dysfunction. Metformin, often the first-line treatment for type 2 diabetes, may be used with caution in mild to moderate CKD but is contraindicated in advanced stages due to the risk of lactic acidosis. Sulfonylureas, except for gliclazide and glimepiride, are generally avoided in CKD because of the prolonged hypoglycemia risk. DPP-4 inhibitors are safer options but may require dose adjustments based on renal function. SGLT2 inhibitors, beneficial for their cardiovascular and renal protective effects, are increasingly recommended, though some are contraindicated in severe CKD. GLP-1 receptor agonists offer a safer profile for CKD patients, with liraglutide and semaglutide being viable options. Ultimately, individualized treatment, frequent monitoring, and adjustments of oral hypoglycemic agents are crucial in managing diabetes in CKD patients.